Lv1
80 积分 2023-08-03 加入
Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis
16天前
已完结
Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)
1个月前
已完结
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023
2个月前
已完结
Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)
2个月前
已完结
Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database
2个月前
已完结
EZH2-mediated development of therapeutic resistance in cancer
2个月前
已完结
The molecular mechanisms and therapeutic potential of EZH2 in breast cancer
2个月前
已完结
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
3个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
4个月前
已完结
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
6个月前
已完结
皖公网安备34019202002308
